Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome

Antzeko izenburuak

• Systematic review of dasatinib in chronic myeloid leukemia
  nork: Breccia, Massimo, et al.
  Argitaratua: (2013)
• Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes
  nork: Breccia, Massimo, et al.
  Argitaratua: (2011)
• Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
  nork: Gattermann, Norbert, et al.
  Argitaratua: (2012)
• MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
  nork: Breccia, Massimo, et al.
  Argitaratua: (2012)
• Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
  nork: Porter, John, et al.
  Argitaratua: (2008)